Laurel H. Messer

Laurel H. Messer

Auto-generated profile, based on publicly available information

Laurel H. Messer

Tandem Diabetes Care, San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
MPMoshe Phillip
Moshe Phillip
RNRevital Nimri
Revital Nimri
RBRichard M Bergenstal
Richard M Bergenstal
KBKatharine Barnard-Kelly
Katharine Barnard-Kelly
TDThomas Danne
Thomas Danne
TBTadej Battelino
Tadej Battelino
The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.

27 December 2019 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
LMLaurel H. Messer
Laurel H. Messer
CBCari Berget
Cari Berget
TVTim Vigers
Tim Vigers
LPLaura Pyle
Laura Pyle
CGCristy Geno
Cristy Geno
GFGregory P. Forlenza
Gregory P. Forlenza

27 December 2017 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
LML. H. Messer
L. H. Messer
RJR. Johnson
R. Johnson
KDK. A. Driscoll
K. A. Driscoll
JJJ. Jones
J. Jones

14 February 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
LMLaurel H. Messer
Laurel H. Messer
GFGregory P. Forlenza
Gregory P. Forlenza
JSJennifer L. Sherr
Jennifer L. Sherr
RWR. Paul Wadwa
R. Paul Wadwa
BBBruce A. Buckingham
Bruce A. Buckingham
RSRobert H. Slover
Robert H. Slover
OBJECTIVE The MiniMed 670G System is the first commercial hybrid closed-loop (HCL) system for management of type 1 diabetes. Using data from adolescent and young adult participants, we compared insulin delivery patterns and time-in-range metrics in HCL (Auto Mode) and open-loop (OL). System alerts, usage profiles, and operational parameters were examined to provide suggestions for optimal clinical use of the system. RESEARCH DESIGN AND METHODS Data from 31 adolescent and young adult participants (14–26 years old) at three clinical sites in the 670G pivotal trial were analyzed. Participants had a 2-week run-in period in OL, followed by a 3-month in-home study phase with HCL functionality enabled. Data were compared between baseline OL and HCL use after 1 week, 1 month, 2 months, and 3 months. RESULTS Carbohydrate-to-insulin (C-to-I) ratios were more aggressive for all meals with HCL compared with baseline OL. Total daily insulin dose and basal-to-bolus ratio did not change during the trial. Time in range increased 14% with use of Auto Mode after 3 months (P < 0.001), and HbA1c decreased 0.75%. Auto Mode exits were primarily due to sensor/insulin delivery alerts and hyperglycemia. The percentage of time in Auto Mode gradually declined from 87%, with a final use rate of 72% (−15%). CONCLUSIONS In transitioning young patients to the 670G system, providers should anticipate immediate C-to-I ratio adjustments while also assessing active insulin time. Users should anticipate occasional Auto Mode exits, which can be reduced by following system instructions and reliably bolusing for meals. Unique 670G system functionality requires ongoing clinical guidance and education from providers.

1 August 2019 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
LMLaurel H. Messer
Laurel H. Messer
CBCari Berget
Cari Berget
GFGregory P. Forlenza
Gregory P. Forlenza
Diabetes Technology & Therapeutics

25 November 2021 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
LMLaurel H. Messer
Laurel H. Messer
CBCari Berget
Cari Berget
LPLaura Pyle
Laura Pyle
TVTim Vigers
Tim Vigers
ECErin Cobry
Erin Cobry
GFGregory Forlenza
Gregory Forlenza
Objective: To describe real-world outcomes for youth using the Tandem t:slim X2 insulin pump with Control-IQ technology (“Control-IQ”) for 6 months at a large pediatric clinic. Methods: Youth with type 1 diabetes, who started Control-IQ for routine care, were prospectively followed. Data on system use and glycemic control were collected before Control-IQ start, and at 1, 3, and 6 months after start. Mixed models assessed change across time; interactions with baseline hemoglobin A1c (HbA1c) and age were tested. Results: In 191 youth (median age 14, 47% female, and median HbA1c 7.6%), percent time with glucose levels 70–180 mg/dL (time-in-range [TIR]) improved from 57% at baseline to 66% at 6 months ( P < 0.001). The proportion of participants reaching TIR target (>70%) doubled from 23.5% at baseline to 47.8% at 3 months, sustaining at 46.7% at 6 months ( P < 0.001). Glucose management indicator (approximation of HbA1c) improved from 7.5% at baseline to 7.1% at 3 months and 7.2% at 6 months ( P < 0.001). Those with higher baseline HbA1c experienced the most substantial improvements in glycemic control. Percent time using the Control-IQ feature was 86.4% at 6 months, and <4% of cohort discontinued use. Conclusion: The Control-IQ system clinically and significantly improved glycemic control in a large sample of youth. System use was high at 6 months, with only a small proportion discontinuing use, indicating potential for sustaining results long term.